Jagsonpal Pharmaceuticals Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Jagsonpal Pharmaceuticals Limited generated cash of $351,660,000, which is less than the previous year. Cash used in financing activities reached the amount of -$89,110,000 last year. Net change in cash is therefore $17,070,000.
Cash Flow
| 2010 | 8.55M | -20.99M | 12.76M |
|---|---|---|---|
| 2011 | 64.56M | -70.08M | 7.11M |
| 2012 | 70.83M | -49.39M | 4.12M |
| 2016 | 90.38M | -20.92M | -64.30M |
| 2018 | -15.75M | -33.71M | -6.00M |
| 2020 | 112.47M | -107.62M | -9.44M |
| 2021 | 282.22M | -22.64M | -68.28M |
| 2023 | 466.54M | -576.70M | -4.56M |
| 2024 | 351.66M | -245.48M | -89.11M |
JAGSNPHARM.NS Cash Flow Statement (2010 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 110.53M | 225.26M | 398.13M | 385.34M | 200.59M | 150.17M | 73.25M | 2.11M | 1.79M |
Operating activities | |||||||||
Net income | 224.63M | 348.08M | 218.72M | 94.14M | -116.26M | 40.75M | 74.56M | 71.79M | 92.41M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 16.62M | 12.05M | 10.86M | 11.29M | 10.62M | 30.93M | 25.35M | 22.00M | 20.84M |
Stock-based compensation expense | 133.1M | 87.65M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 133.1M | 87.65M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 91.54M | -55.56M | 87.89M | -7.03M | 142.59M | 31.98M | 0 | 0 | 0 |
Inventories | 53.1M | 90.65M | -3.99M | 33.67M | -38.14M | -67.75M | 126.63M | -1.25M | -4.22M |
Accounts payable | -89.82M | -19.62M | 63.40M | -1.51M | 1.10M | 18.57M | 0 | 0 | 0 |
Cash generated by operating activities | 351.66M | 466.54M | 282.22M | 112.47M | -15.75M | 90.38M | 70.83M | 64.56M | 8.55M |
Investing activities | |||||||||
Purchases Of Investments | -1.35B | -1.03B | -41.72M | -113.86M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2.48M | -3.17M | -4.69M | -20.68M | -38.27M | -27.48M | -53.09M | -70.08M | -20.99M |
Acquisitions Net | 0 | 12.96M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -245.48M | -576.70M | -22.64M | -107.62M | -33.71M | -20.92M | -49.39M | -70.08M | -20.99M |
Financing activities | |||||||||
Common Stock Issued | 56.35M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | -130.99M | 0 | -26.2M | -13.1M | -2.62M | -2.62M | -13.09M | 0 | 0 |
Repurchases of common stock | 0 | 0 | -36.94M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 8.79M | 3.72M | -8.17M | 0 | 0 | 0 |
Cash used in financing activities | -89.11M | -4.56M | -68.28M | -9.44M | -6.00M | -64.30M | 4.12M | 7.11M | 12.76M |
Net Change In Cash | 17.07M | -114.73M | 191.29M | -4.60M | -55.47M | 5.15M | 25.55M | 1.58M | 322.99K |
Cash at end of period | 127.6M | 110.53M | 589.42M | 380.74M | 145.12M | 155.33M | 98.80M | 3.70M | 2.11M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |